

GLOBAL, REGIONAL, AND COUNTRY-LEVEL COVERAGE OF TESTING AND TREATMENT FOR HIV AND HEPATITIS C INFECTION AMONG PEOPLE WHO INJECT DRUGS: A SYSTEMATIC REVIEW

Authors:

Hajarizadeh B¹, Kairouz A¹, Cunningham E¹, Ottaviano S², Willing A¹, Ireland J², Webb P², Colledge-Frisby S², Wheeler A¹, Leung J^{2,3}, Tran LT², Price O², Vickerman P⁴, Farrell M², Hickman⁴, Dore GJ¹, Bergenström A⁵, Degenhardt L², Grebely J¹

¹The Kirby Institute, UNSW, Sydney, Australia ²National Drug and Alcohol Research Centre, UNSW, Sydney, Australia ³National Centre for Youth Substance Use Research, University of Queensland, Brisbane, Australia ⁴Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK ⁵European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal

Background:

People who inject drugs (PWID) are disproportionately affected by HIV and HCV infections in most countries. Global data on HIV and HCV testing and treatment coverage among PWID are limited. This systematic review evaluated country-level, regional, and global coverage of HIV and HCV testing and treatment among PWID.

Methods:

We searched bibliographic databases (MEDLINE, Embase, PsycINFO) and grey literature for studies, published until April-2022, that evaluated the proportion of PWID who received testing or treatment for HIV or HCV. For each country, we estimated the proportion of PWID recently tested for HIV antibody (past 12 months), and those ever tested for HCV antibody and HCV-RNA. We also estimated the proportion of PWID with HIV currently receiving antiretroviral therapy, and those with HCV ever receiving HCV treatment. Regional and global estimates, weighted by PWID population size, were generated where sufficient data were available.

Results:

Data of recent HIV antibody testing and ever HCV antibody testing were available for 67 and 49 countries, respectively (Figure). Globally, we estimated that 49% of PWID were recently tested for HIV antibody [uncertainty interval (UI): 43-54%; range: <1-86%], and 47% had ever tested for HCV antibody (UI: 43-51%; range: <1-93%). HCV RNA testing data were available from three countries. Coverage of HIV antibody and HCV antibody testing was >75% in four and 15 countries, respectively. Estimated uptake of current HIV treatment (18 countries) ranged from 3% to 82% across countries. Estimated uptake of ever HCV treatment (23 countries) ranged from 2 to 89% across countries. Uptake of HIV and HCV treatment was >75% in two and one countries, respectively.


Conclusion:

HIV and HCV testing and treatment uptake among PWID was highly variable, and sub-optimal in most countries. Strategies to improve access to HIV and HCV care among PWID and availability of public health surveillance are required.

Disclosure of Interest Statement:

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication are those of the authors and do not necessarily represent the position of the Australian Government. The study was funded by the Australian National Health and Medical Research Council (NHMRC) and the United Kingdom National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation

A.



B.




Figure: Estimated proportion of people who inject drugs tested for HIV antibody in the past 12 months (A) and those ever tested for HCV antibody (B), by country
Low: <40%; Moderate: 40-75%; High >75%